UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

The HER2-low revolution in breast oncology: steps forward and emerging challenges

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231152842-17588359231152842

2023

Link zum Volltext

Verfügbarkeit prüfen

Future potential targets of antibody-drug conjugates in breast cancer

Breast (Edinburgh), 2023-06, Vol.69, p.312-322

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Cancers, 2022-09, Vol.14 (17), p.4278

2022

Link zum Volltext

Verfügbarkeit prüfen

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting

Cancers, 2024-01, Vol.16 (2), p.281

2024

Link zum Volltext

Verfügbarkeit prüfen

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

Investigational new drugs, 2022-10, Vol.40 (5), p.1133-1136

2022

Link zum Volltext

Verfügbarkeit prüfen

Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates

Critical reviews in oncology/hematology, 2024-03, Vol.195, p.104270-104270, Article 104270

2024

Link zum Volltext

Verfügbarkeit prüfen

A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs

Expert opinion on drug metabolism & toxicology, 2023-07, Vol.19 (7), p.389-403

2023

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer

Cancer treatment reviews, 2024-02, Vol.123, p.102669-102669, Article 102669

2024

Link zum Volltext

Verfügbarkeit prüfen

A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data

European journal of cancer (1990), 2023-09, Vol.190, p.112958-112958, Article 112958

2023

Link zum Volltext

Verfügbarkeit prüfen

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology

The oncologist (Dayton, Ohio), 2024-06, Vol.29 (6), p.504-510

2024

Link zum Volltext

Verfügbarkeit prüfen

Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers

The oncologist (Dayton, Ohio), 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis

The oncologist (Dayton, Ohio), 2024-05, Vol.29 (7), p.560-565

2024

Link zum Volltext

Verfügbarkeit prüfen

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

European journal of cancer (1990), 2023-09, Vol.190, p.112944-112944, Article 112944

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience

European journal of cancer (1990), 2023-04, Vol.183, p.79-89

2023

Link zum Volltext

Verfügbarkeit prüfen

Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents

The oncologist (Dayton, Ohio), 2024-01, Vol.29 (1), p.75-83

2024

Link zum Volltext

Verfügbarkeit prüfen

Variant allele frequency: a decision-making tool in precision oncology?

Trends in cancer, 2023-12, Vol.9 (12), p.1058-1068

2023

Link zum Volltext

Verfügbarkeit prüfen

530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A603-A604

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer

Expert opinion on pharmacotherapy, 2023-05, Vol.24 (7), p.789-801

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment optimization in early triple negative breast cancer

Expert review of anticancer therapy, 2023-10, Vol.23 (10), p.1107-1116

2023

Link zum Volltext

Verfügbarkeit prüfen

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Cancer treatment reviews, 2024-07, Vol.128, p.102761-102761, Article 102761

2024

Link zum Volltext

Verfügbarkeit prüfen

Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer

Breast Cancer Research and Treatment, 2023, Vol.188, p.237-281

2023

Link zum Volltext

Verfügbarkeit prüfen

Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3063-3063

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(21)
Buchkapitel
(1)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Oncology
(16)
Humans
(9)
Breast Cancer
(7)
Immunotherapy
(7)
Cancer
(5)
Mutation
(4)
Precision Medicine
(4)
Precision Oncology
(4)
Antibody-Drug Conjugates
(3)
Biomarker
(3)
Biomarkers
(3)
Development And Progression
(3)
Female
(3)
Pharmacology & Pharmacy
(3)
Targeted Therapy
(3)
Tumors
(3)
Antibody–drug Conjugates
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The HER2-low revolution in breast oncology: steps forward and emerging challenges

Future potential targets of antibody-drug conjugates in breast cancer

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates

A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs

Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer

A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology

Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers

Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience

Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents

Variant allele frequency: a decision-making tool in precision oncology?

530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer

Treatment optimization in early triple negative breast cancer

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer

Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents

Suchergebnisse filtern